Clinical trial
A Full-Factorial, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Dose Efficacy and Safety Study of an Acetaminophen/Naproxen Sodium Fixed Combination, Acetaminophen, and Naproxen Sodium in Postoperative Dental Pain
Name
CCSPAA005199
Description
The purpose of this study is to evaluate how well a fixed combination of acetaminophen/naproxen sodium relieves postoperative dental pain compared with acetaminophen, naproxen sodium and placebo.
Trial arms
Trial start
2023-05-22
Estimated PCD
2024-05-17
Trial end
2024-05-31
Status
Recruiting
Phase
Early phase I
Treatment
Acetaminophen/Naproxen Sodium Fixed Combination
Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.
Arms:
Acetaminophen/Naproxen Sodium Fixed Combination
Naproxen Sodium
Naproxen Sodium will be administered orally.
Arms:
Naproxen Sodium
Acetaminophen
Acetaminophen will be administered orally.
Arms:
Acetaminophen
Placebo
Placebo will be administered orally.
Arms:
Naproxen Sodium, Placebo
Size
440
Primary endpoint
Time-weighted Sum of Pain Intensity Difference from 0 to 12 Hours After Dosing (SPID 0-12)
0 to 12 hours
Eligibility criteria
Inclusion Criteria:
* Weigh 100 pounds or greater and have a body mass index (BMI) of 17.5 to 30.4 (inclusive) at screening
* Surgical removal of three or four third molars, of which, two must be mandibular impactions
* Meets requirements for post-surgical pain level
* Females of childbearing potential and males agree to contraceptive requirements of study
* Have a negative urine drug screen at screening, and on day of surgical procedure
Exclusion Criteria:
* Pregnant female, breastfeeding, trying to become pregnant or male with pregnant partner or partner currently trying to become pregnant
* Have a known allergy or hypersensitivity to naproxen (or other NSAIDs including aspirin) or to acetaminophen, oxycodone or other opioids
* Not able to swallow whole large tablets or capsules
* History of any condition(s) in investigator's opinion, may jeopardize subject safety, well-being and integrity of study
* Use analgesics 5 or more times per week
* History of chronic tranquilizer use, heavy drinking, or substance abuse, as judged by the investigator site staff, in the last 5 years
* Use any immunosuppressive drugs within 2 weeks of surgical procedure
* History of endoscopically documented peptic ulcer disease or bleeding disorder in the last 2 years
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Postoperative dental pain following third molar extraction.', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 440, 'type': 'ESTIMATED'}}
Updated at
2024-05-08
1 organization
4 products
1 indication
Organization
Johnson & Johnson ConsumerProduct
AcetaminophenIndication
PainProduct
NaproxenProduct
Placebo